Pacira BioSciences, Inc. PCRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.14M— | $7.03M— | —— | —— | —— | ||
| $91.19M+11.8% | $91.02M+15.5% | $90.92M+19.6% | $89.99M+21.3% | $81.53M+9.6% | ||
| $56.49M+7.4% | $57.5M+12.4% | $56.27M+9.6% | $55.52M+9.7% | $52.57M+7.2% | ||
| —— | —— | $13.73M-42.1% | $6.77M-75.4% | $18.56M-29.8% | ||
| $2.73M-19.9% | $3.02M-6.3% | $3.28M-11.9% | $3.49M-2.0% | $3.41M-2.4% | ||
| $20.87M+572% | $10.74M+38.6% | $14.59M+295% | $9.57M+67.9% | $3.11M-63.2% | ||
| —— | —— | $45.8M+198% | $44.72M+295% | $36.97M+872% | ||
| -$9M— | -$5.6M— | —— | —— | —— | ||
| -$8.15M— | $6.85M— | —— | —— | —— | ||
| —— | —— | —— | $17.27M— | $6.04M— | ||
| —— | —— | —— | $14.41M— | $4.57M— | ||
| —— | —— | —— | —— | —— | ||
| $142.22M-19.1% | $151.99M-19.7% | $141.44M-30.6% | $134.52M-30.8% | $175.75M-4.8% | ||
| $9.51M-41.8% | $15.33M+44.2% | $17.23M+67.1% | $17.46M+81.5% | $16.35M+43.0% | ||
| —— | —— | —— | —— | $16.7M— | ||
| $71.41M-73.1% | $141.04M-44.1% | $158.65M-31.9% | $221.12M+27.2% | $265.79M+84.4% | ||
| $227.06M+10.5% | $273.81M+52.5% | $273.61M+62.2% | $240.53M+53.4% | $205.46M+33.3% | ||
| $144.55M+255% | $99.48M+219% | $79.78M+207% | -$16M+28.5% | -$93.38M-55,026% | ||
| $198.37M+958% | $148.33M+493% | $106.33M+467% | $62.54M+400% | $18.75M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0-100% | ||
| $9.79M+1,366% | $5.62M+1,044% | $5.55M+968% | $5.58M+1,042% | $668K+507% | ||
| -$426.03M— | -$369.63M— | —— | —— | —— | ||
| -$39K— | -$77K— | $337K— | $204K— | —— | ||
| -$150.26M-249% | -$129.19M-204% | -$98.38M-166% | $54.52M— | $100.65M— | ||
| $14.12M-0.3% | $15.24M-1.2% | $15.62M+21.1% | $16.12M+16.6% | $14.16M+1.4% | ||
| —— | —— | $10.39M-12.5% | $14.59M+77.1% | $11.55M+195% | ||
| —— | —— | —— | —— | $7.48M+41.4% | ||
| —— | —— | —— | —— | $3.28M-9.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0+100% | -$541.25K+66.7% | -$1.08M0.0% | -$1.62M-200% | ||
| —— | $6.85M-52.5% | $8.75M+61.3% | $10.64M+397% | $12.54M+200% | ||
| —— | —— | —— | $17.27M— | $6.04M— | ||
| —— | —— | —— | —— | -$5.72M— | ||
| $71.41M-73.1% | $141.04M-44.1% | $158.65M-31.9% | $221.12M+27.2% | $265.79M+84.4% | ||
| $227.06M+10.5% | $273.81M+52.5% | $273.61M+62.2% | $240.53M+53.4% | $205.46M+33.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| —— | $1.79M— | $1.34M— | $896K— | $448K— | ||
| —— | —— | —— | —— | —— | ||
| $132.71M-16.7% | $136.66M-23.5% | $124.2M-35.8% | $117.07M-36.6% | $159.4M-8.0% | ||
| $132.71M-16.7% | $136.66M-23.5% | $124.2M-35.8% | $117.07M-36.6% | $159.4M-8.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pacira BioSciences, Inc. generate?
- Pacira BioSciences, Inc. (PCRX) generated $142.2M in operating cash flow over the trailing twelve months.
- What is Pacira BioSciences, Inc.'s free cash flow?
- After $9.5M of capital expenditures, Pacira BioSciences, Inc.'s free cash flow was $132.7M over the trailing twelve months, down 16.8% year over year.
- Where does Pacira BioSciences, Inc.'s cash flow data come from?
- Every line is extracted from Pacira BioSciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
